Navigation Links
Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Date:11/2/2010

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions on November 2, 2010 in Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition of Factor IXa by Subcutaneous RB006 with Active Reversal: First-in-Human Experience with the REG2 System."

The REG2 system is intended for use in venous thrombosis indications.  This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.  It demonstrated that a single subcutaneous injection of RB006 (aka pegnivacogin) resulted in dose-dependent inhibition of Factor IXa with effects that persisted longer than one week after injection. The data is promising for future development of REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC and William Wargin, Ph.D., President of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... August 27, 2015 According to a new ... Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage ... 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is poised ... in 2015, at a CAGR of 11.4 % from 2015 to ... ma rket data T ables and 65 ...
(Date:8/27/2015)... --  Women Grow , the fastest-growing professional networking organization for ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... educational sessions. CWCBExpo in LA will take place September 16-18, ... Center in Los Angeles, CA , and ... the marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... Aug. 27, 2015  A mere one in seven ... Allen Hamilton . A new white paper ... are impeding and disrupting manufacturers, success. The ... Improve Value In Product Development Processes provides insight ... and how it affects the product development process resulting ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... no stent thrombosis or MACE,after one year, ... 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,welcomed the ... FIRST, II,and III Clinical Trials, reaffirming prior ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System and XIENCE(TM) V ...
... of Choroidal,Neovascularization (CNV) in an AMD Model, SAN ... ,the category leader in therapeutic agents against bioactive ... of human age-related macular degeneration (AMD). , The ... the,Association of Research in Vision and Ophthalmology (ARVO) ...
Cached Medicine Technology:SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout ... go deep sea diving. The act of recreational diving exposes the body ... reasons, it is vital that all recreational and professional divers undergo regular comprehensive ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... of the top 5 millionaire dating sites . According to the listings, ... the second best in this category. , A spokesperson of Top5MillionaireDatingSites.com ...
(Date:8/28/2015)... ... , ... Inc. magazine today ranked PREVENT Life Safety No. 3660 ... private companies. The list was unveiled online at Inc.com and is the most competitive ... years, PREVENT ranks higher on the list than any other company in their industry. ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... tailor therapy regimen to individuals, experts say , , TUESDAY, ... affect the way children respond to treatment for lymphoblastic ... children suffering from this type of blood and bone ... to treatment. Now researchers think they know why. , ...
... radiation indicates need for earlier screening, study notes, , , ... female childhood cancer survivors under the age of 40 ... are not following the recommended advice to get screening ... The recommendation suggests starting screening mammograms at age 25, ...
... Ill., Jan. 27 EngagementHealth, LLC., an innovator ... launch of its comprehensive disease prevention and health ... RBNF ). Rurban Financial is a leading ... services, and bank data and item processing, headquartered ...
... point-of-use and central pharmacy automation solutionsMOUNTAIN VIEW, Calif., Jan. ... a leading provider of system solutions to acute healthcare ... by Emory Healthcare for Omnicell point-of-use and central pharmacy ... (NASDAQ: OMCL ) is a leading provider ...
... 27, 2009 Environmental Tobacco Smoke (ETS) commonly called ... account for complications during pregnancy and birth. It is ... than do whites from smoking and ETS exposure. In ... the American Journal of Preventive Medicine , researchers ...
... Jan. 27 Trust for America,s Health (TFAH) applauds ... funding to improve the health of Americans while stimulating ... "This funding is desperately needed to revitalize and ... be putting more Americans to work in programs that ...
Cached Medicine News:Health News:In Kids, Genes May Affect Leukemia Treatment 2Health News:In Kids, Genes May Affect Leukemia Treatment 3Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF) 2Health News:Avoiding secondhand smoke during pregnancy 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Medicine Products: